If the European Union(EU) does not reconsider its decision of suspending the sale of around 700 generic drugs which were approved on the basis of clinical trials by GVK Bioscience, India may go for WTO action against EU, says the firm’s CEO Manni Kantipudi.
The company GVK conducts clinical research for domestic and foreign drug makers.
Last year the French Watchdog has inspected a GVK Biosciences manufacturing plant in southern India and has found manipulation of data from electrocardiograms (ECG) for at least five years.
The French regulator said at the time that suspensions were taken out of precaution and there was no reason to suggest the drugs were ineffective or harmful.
“After an appeal by the company, the Indian government set up a panel of experts last year to investigate the matter and found no manipulation”, Kantipudi said.
“An Indian government delegation visited the European authorities between February and March to ask that the suspension be reconsidered”, he said.
“There are some legal options, but we will see what comes out of these diplomatic talks and then we and the commerce ministry will decide on what to do,” Katipudi said.